Back to Stocks

ZEOX

Zeo ScientifiX, Inc.
1 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

The investment narrative has evolved from a speculative clinical-stage bet to a race for commercial viability. The primary driver is now the 'Florida Pivot,' where the company is utilizing a specific regulatory window to sell stem cell-derived products.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The bear case has intensified as the company's financial structure becomes increasingly fragile. The reliance on convertible notes and the presence of significant related-party receivables suggest a business struggling to find sustainable funding.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ZEOX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Zeo ScientifiX is attempting a high-stakes transition from a clinical-stage biotech to a commercial regenerative medicine provider.…

Latest Available Quarter (Q2 '26 (10-Q))

Core Takeaway

ZEO is successfully selling products in Florida but is running out of money to fund the rest of its operations.

Investor Lens

Investors must weigh the 79% gross margins against the risk of a total regulatory shutdown by the FDA.

Watch Next

The outcome of the 2026 annual meeting and any new equity financing rounds.

Calculated Financial Trajectory (Click to filter signals)

Revenue (M)4.03
Q2 FY '25: 2.01→Q2 FY '26: 4.03
Net Income (M)-1.00
Q2 FY '25: -1.95→Q2 FY '26: -1.00
Gross Margin (%)25.0%
Q2 FY '25: 19.5%→Q2 FY '26: 25.0%
Net Debt (M)0.62
Q2 FY '25: 0.45→Q2 FY '26: 0.62

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.27Q2 '26 (10-Q)

Signal Timeline

bearishJun 15

Company continues to report net losses despite revenue growth.

earnings miss
70%
bullishJun 15

Gross margins remain strong at 79% as the company scales.

margin expansion
80%
bearishJun 15

Heavy reliance on equity sales and convertible notes to fund operations.

dilution risk
90%

Filing History

10-QJun 15, 2026
Expand Sequence

The latest 10-Q presents a stark contrast between accelerating commercial traction and a fragile balance sheet. While the company has successfully raised capital and grown its top line, it continues to operate at a loss with a significant accumulated deficit. The outcome for investors now depends on whether the company can scale its Florida-based operations fast enough to achieve cash-flow positivity before its current liquidity evaporates.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.